Pivotal readout

Mangaciclanol Advances to Phase 3

GE HealthCare reported that mangaciclanol met the Phase 2 primary endpoint, with overall diagnostic preference similar to gadobutrol in central nervous system imaging. The company selected a 0.1 mmol/kg dose for Phase 3; mangaciclanol was well tolerated in Phase 2, with no safety concerns identified.

The investigational agent has FDA Fast Track designation. Preliminary Phase 2 results will be presented at RSNA 2026.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call